Related Experiment Video
Updated: Jun 1, 2026

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
Published on: November 2, 2014
Changes in the management and outcome of central nervous system involvement from ovarian cancer since 1994
Gennaro Cormio1, Vera Loizzi, Maddalena Falagario
1Department of Gynecology, Obstetrics and Neonatology, Gynecologic Oncology Unit, University of Bari, Bari, Italy. n.cormio@gynecology2.uniba.it
Objective:
To identify differences in the management and outcome of patients with central nervous system metastases from epithelial ovarian cancer.
Methods:
The clinical and pathologic characteristics, treatment, and outcome of 23 patients with brain metastases from epithelial ovarian cancer who were treated during 1982-1994 were compared with those of 20 patients treated during 1995-2010 at the same center.
Results:
No differences were found in terms of primary tumor characteristics, time interval from ovarian cancer diagnosis to brain involvement diagnosis, sites of metastasis, and presence of extracranial disease. The main difference between the 2 groups was the therapeutic approach. During 1982-1994, most patients received radiotherapy only, whereas most patients during 1995-2010 underwent surgical resection followed by radiotherapy and/or chemotherapy. The duration of survival during 1982-1994 was 5 months, which was significantly shorter than the duration of survival (18 months) during 1995-2010.
Conclusion:
An aggressive multimodal treatment approach might prolong the survival of patients with brain involvement from ovarian cancer.
Related Concept Videos
Treatment Resistant Cancers
Treatment Resistent Cancers
Hormonal Control of the Ovarian Cycle
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
